Vertex claimed the two drugs in the deal could eventually bring in more than $5 billion annually. Still, the high price it ...

The transaction's two focuses, Palsonify and atumelnant, have combined peak sales potential of more than $5 billion, Vertex ...

A genomic analysis platform has been developed that can identify the genes behind rare endocrine disorders more quickly and accurately.

Crinetics Pharmaceuticals (NASDAQ:CRNX | CRNX Price Prediction) shares have climbed 99% just this week, from $42.03 at Monday ...

Neurocrine Biosciences (NasdaqGS:NBIX) has begun a Phase 2 pediatric study of crinecerfont in children under 4 years with ...

Vertex Pharma to buy Crinetics Pharmaceuticals for $10 billion: Boston Wednesday, July 8, 2026, 14:00 Hrs [IST] Vertex Pharmaceuticals Incorporated, a global biotechnology company ...

Gross SC-islet morphology and size were maintained, yet the fraction of NKX6.1-positive β cells fell substantially, pointing ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of ...

As of Friday, July 10, Viking Therapeutics, Inc.’s VKTX share price has dipped by 5.04%, which has investors questioning if ...

Menopause. Suddenly, the topic is everywhere in the headlines, in our news feeds, on podcasts. Until recently, this normal ...

With expected close this quarter, the stock should converge toward the deal price as deal certainty rises and spreads tighten ...

Carla Moran is a consultant endocrinologist at the Beacon Hospital, Dublin ...